83
True
United States
The website discusses genetic predictors of GLP1 receptor agonist weight loss and side effects, highlighting significant genetic variants affecting efficacy and side effects, and the prevalence of obesity and GLP1 medication usage in the USA.
The claims regarding the efficacy and side effects of GLP1 receptor agonists, as well as the prevalence of obesity and medication usage in the USA, are well-supported by multiple high-quality sources. Studies published in reputable journals confirm the genetic associations with medication efficacy and side effects, while CDC and other authoritative data sources corroborate the statistics on obesity and medication usage. Overall, the evidence strongly supports the factual accuracy of these claims.
Individual Claims
85
True
Medical
A missense variant in GLP1R is associated significantly with increased efficacy of GLP1 medications.
Multiple sources, including a study published in Nature, confirm that a missense variant in GLP1R is associated with increased efficacy of GLP1 medications, resulting in additional weight loss per effect allele. This is supported by evidence from reputable sources like Scientific American and Nature.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
90
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
85
Evidence Summary
3 web sources confirm the claim, including a study in Nature.
80
True
Medical
Variation in GLP1R and GIPR is linked to GLP1 medication-related nausea or vomiting.
Evidence from multiple sources, including scientific journals, supports the claim that variations in GLP1R and GIPR are linked to nausea or vomiting related to GLP1 medications. This is corroborated by studies on the role of GIPR in reducing nausea.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
80
Evidence Summary
3 web sources support the claim, including scientific journals.
85
True
Health
Approximately 40% of adults in the USA are classified as living with obesity.
The CDC and other reputable sources confirm that approximately 40% of U.S. adults are classified as living with obesity. This statistic is consistent with recent data from 2021 to 2023.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
90
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
85
Evidence Summary
3 web sources confirm the claim, including CDC data.
80
True
Medical
One in eight people in the USA have used a GLP1 receptor agonist medication.
Multiple sources, including Statista and RAND, confirm that approximately 12.4% of U.S. adults have used GLP1 receptor agonist medications, supporting the claim that one in eight people have used these drugs.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
80
Evidence Summary
3 web sources support the claim, including Statista and RAND data.
85
True
Medical
Participants reported greater BMI loss using tirzepatide compared with semaglutide.
Multiple studies, including a network meta-analysis, confirm that tirzepatide results in greater BMI loss compared to semaglutide. This is supported by evidence from reputable sources like PMC and JAMA Network.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
90
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
85
Evidence Summary
3 web sources confirm the claim, including a network meta-analysis.
